Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3726-3735

  Lv, Zhi ^a   Peng, Guoli ^b   Liu, Weihua ^a   Xu, Hufeng ^a   Su, JianRong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Gongan Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; GENTAMICIN; KANAMYCIN; METRONIDAZOLE; RNA 16S; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTEROIDACEAE; BACTEROIDALES; BACTEROIDETES; C57BL 6 MOUSE; CAMPYLOBACTERALES; CECUM; CLOSTRIDIA; CLOSTRIDIACEAE; CLOSTRIDIALES; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DELTAPROTEOBACTERIA; DISEASE ACTIVITY SCORE; DRUG EFFECT; DRUG EFFICACY; ENTEROBACTERIACEAE; ENTEROBACTERIALES; EPSILONPROTEOBACTERIA; EXPERIMENTAL COLITIS; FECES ANALYSIS; FIRMICUTES; GAMMAPROTEOBACTERIA; HISTOPATHOLOGY; ILEUM; INFECTION PREVENTION; INTESTINE FLORA; INTESTINE INJURY; LACHNOSPIRACEAE; LACTOBACILLACEAE; LACTOBACILLALES; MALE; MICROBIAL COMMUNITY; MORTALITY; MOUSE; MOUSE MODEL; NONHUMAN; OUTCOME ASSESSMENT; PORPHYROMONADACEAE; PRIORITY JOURNAL; PROTEOBACTERIA; RECURRENT INFECTION; SEQUENCE ANALYSIS; SINGLE DRUG DOSE; SURVIVAL; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; COLITIS; COMBINATION DRUG THERAPY; DISEASE MODEL; DNA SEQUENCE; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GENETICS; MICROBIOLOGY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; RANDOMIZATION; RECURRENT DISEASE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BASE SEQUENCE; BERBERINE; CLOSTRIDIUM DIFFICILE; COLITIS; DISEASE MODELS, ANIMAL; DNA, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FECES; GASTROINTESTINAL MICROBIOME; MICE; MICE, INBRED C57BL; RANDOM ALLOCATION; RECURRENCE; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA; VANCOMYCIN; WEIGHT LOSS;

EID: 84935865485     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04794-14     Document Type: Article

References (26)

1. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. 2011. Mouse relapse model of Clostridium difficile infection. Infect Immun 79:2856-2864. http://dx.doi.org/10.1128/IAI.01336-10.
2. Gough E, Shaikh H, Manges AR. 2011. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:994-1002. http://dx.doi.org/10.1093/cid/cir632.
3. Lo Vecchio A, Zacur GM. 2012. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 28:1-9. http://dx.doi.org/10.1097/MOG.0b013e32834bc9a9.
4. Birdsall TC, Kelly GS. 1997. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev 2:94-103.
5. Imanshahidi M, Hosseinzadeh H. 2008. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 22:999-1012. http://dx.doi.org/10.1002/ptr.2399.
6. Yan F, Wang L, Shi Y, Cao H, Liu L, Washington MK, Chaturvedi R, Israel DA, Cao H, Wang B, Peek RM Jr, Wilson KT, Polk DB. 2012. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol 302:G504-G514. http://dx.doi.org/10.1152/ajpgi.00312.2011.
7. Rea MC, Dobson A, O'Sullivan O, Crispie F, Fouhy F, Cotter PD, Shanahan F, Kiely B, Hill C, Ross RP. 2011. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A108(Suppl 1):S4639-S4644. http://dx.doi.org/10.1073/pnas.1001224107.
8. Han J, Lin H, Huang W. 2011. Modulating gut microbiota as an antidiabetic mechanism of berberine. Med Sci Monit 17:RA164-RA167. http://dx.doi.org/10.12659/MSM.881842.
9. Domadia PN, Bhunia A, Sivaraman J, Swarup S, Dasgupta D. 2008. Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry 47:3225-3234. http://dx.doi.org/10.1021/bi7018546.
10. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002.
11. Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP. 2008. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother 52:1121-1126. http://dx.doi.org/10.1128/AAC.01143-07.
12. Kamada N, Inoue N, Hisamatsu T, Okamoto S, Matsuoka K, Sato T, Chinen H, Hong KS, Yamada T, Suzuki Y, Suzuki T, Watanabe N, Tsuchimoto K, Hibi T. 2005. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 11:455-463. http://dx.doi.org/10.1097/01.MIB.0000158158.55955.de.
13. Meyer M, Kircher M. 2010. Illumina sequencing library preparation for highly multiplexed target capture and sequencing. Cold Spring Harb Protoc 2010:pdb.prot5448. http://dx.doi.org/10.1101/pdb.prot5448.
14. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. 2013. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 41: D590-D596. http://dx.doi.org/10.1093/nar/gks1219.
15. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335-336. http://dx.doi.org/10.1038/nmeth.f.303.
16. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. 1999. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 20:43-50. http://dx.doi.org/10.1086/501553.
17. Howerton A, Patra M, Abel-Santos E. 2013. A new strategy for the prevention of Clostridium difficile infection. J Infect Dis 207:1498-1504. http://dx.doi.org/10.1093/infdis/jit068.
18. Schnitt SJ, Antonioli DA, Goldman H. 1983. Massive mural edema in severe pseudomembranous colitis. Arch Pathol Lab Med 107:211-213.
19. Zhou H, Mineshita S. 2000. The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. J Pharmacol Exp Ther 294:822-829.
20. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2:145-158. http://dx.doi.org/10.4161/gmic.2.3.16333.
21. Sekirov I, Tam NM, Jogova M, Robertson ML, Li Y, Lupp C, Finlay BB. 2008. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect Immun 76:4726-4736. http://dx.doi.org/10.1128/IAI.00319-08.
22. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. 1997. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 25:729-732. http://dx.doi.org/10.1086/513755.
23. Yuan J, Shen XZ, Zhu XS. 1994. Effect of berberine on transit time of human small intestine. Zhongguo Zhong Xi Yi Jie He Za Zhi 14:718-720.
24. Howerton A, Ramirez N, Abel-Santos E. 2011. Mapping interactions between germinants and Clostridium difficile spores. J Bacteriol 193:274-282. http://dx.doi.org/10.1128/JB.00980-10.
25. Sorg JA, Sonenshein AL. 2010. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 192:4983-4990. http://dx.doi.org/10.1128/JB.00610-10.
26. Sack RB, Froehlich JL. 1982. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infect Immun 35:471-475.